Outlook Therapeutics (OTLK) Cash from Financing Activities (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Cash from Financing Activities data on file, last reported at $6.9 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $6.9 million, down 62.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.2 million (up 93.81% YoY), and the FY2025 annual result was $45.0 million, down 25.43% from the prior year.
• Cash from Financing Activities declined to $6.9 million in Q1 2026 per OTLK's latest filing, from $15.5 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $56.1 million in Q1 2024 and troughed at -$11.3 million in Q2 2022.
• A 5-year average of $10.0 million and a median of $3.3 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities tumbled 516.26% in 2022, then surged 54839.96% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $43.8 million in 2022, then tumbled by 100.01% to -$3183.0 in 2023, then surged by 54839.96% to $1.7 million in 2024, then soared by 791.51% to $15.5 million in 2025, then sank by 55.59% to $6.9 million in 2026.
• Business Quant data shows OTLK's Cash from Financing Activities at $6.9 million in Q1 2026, $15.5 million in Q4 2025, and $11.6 million in Q3 2025.